OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
30045158

B-SOFT Co Ltd

Advanced Medical Equipment & TechnologyVerified

B-SOFT's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. However, the company's liquidity is rated as medium, with a current ratio of 2.38, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow is negative at -390.36 million CNY, and operating cash flow is also negative at -21.20 million CNY, signaling cash flow constraints. Profitability metrics are weak, with a return on equity (ROE) of -10.02% and a return on assets (ROA) of -7.61%. These figures are below the typical thresholds for healthy performance in the healthcare equipment industry. The company reported a net loss of 401.65 million CNY and an operating loss of 414.32 million CNY, indicating significant operational challenges. Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in the healthcare equipment segment. Revenue concentration data is not provided, but the absence of disclosed international operations suggests a domestic focus. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Historical revenue for the latest period was 1.05 billion CNY, but the lack of prior-year data prevents a year-over-year comparison. Analysts have assigned a mean price target of 6.37 CNY, with a median of 6.38 CNY, and a strong buy recommendation from two analysts. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The dilution risk is currently low, with no near-term pressure from share issuance or convertible instruments. However, the company's operating losses and negative cash flows could necessitate future capital raises, which may dilute existing shareholders. Recent events include the publication of the latest financial results, which show a significant operating and net loss. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.

30-day price · 300451(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyB-SOFT Co Ltd
Ticker300451.SZ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. B-SOFT Co Ltd is a Chinese company specializing in healthcare equipment, providing products and services in the advanced medical equipment and technology sector.

Classification. B-SOFT is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

B-SOFT's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. However, the company's liquidity is rated as medium, with a current ratio of 2.38, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow is negative at -390.36 million CNY, and operating cash flow is also negative at -21.20 million CNY, signaling cash flow constraints. Profitability metrics are weak, with a return on equity (ROE) of -10.02% and a return on assets (ROA) of -7.61%. These figures are below the typical thresholds for healthy performance in the healthcare equipment industry. The company reported a net loss of 401.65 million CNY and an operating loss of 414.32 million CNY, indicating significant operational challenges. Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in the healthcare equipment segment. Revenue concentration data is not provided, but the absence of disclosed international operations suggests a domestic focus. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Historical revenue for the latest period was 1.05 billion CNY, but the lack of prior-year data prevents a year-over-year comparison. Analysts have assigned a mean price target of 6.37 CNY, with a median of 6.38 CNY, and a strong buy recommendation from two analysts. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The dilution risk is currently low, with no near-term pressure from share issuance or convertible instruments. However, the company's operating losses and negative cash flows could necessitate future capital raises, which may dilute existing shareholders. Recent events include the publication of the latest financial results, which show a significant operating and net loss. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.
Key takeaways
  • B-SOFT has a low debt-to-equity ratio but faces liquidity constraints due to negative free and operating cash flows.
  • The company is unprofitable, with a return on equity of -10.02% and a return on assets of -7.61%.
  • Analysts have a positive outlook, with a mean price target of 6.37 CNY and a strong buy recommendation.
  • The company's growth trajectory is unclear, with no specific revenue growth projections provided.
  • Liquidity risk is a key concern, as the company has negative net cash after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.05B
Gross profit$333.5M
Operating income-$414.3M
Net income-$401.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$21.2M
CapEx-$172.3M
Free cash flow-$390.4M
Total assets$5.28B
Total liabilities$1.27B
Total equity$4.01B
Cash & equivalents
Long-term debt$75.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.01B
Net cash-$75.2M
Current ratio2.4
Debt/Equity0.0
ROA-7.6%
ROE-10.0%
Cash conversion5.0%
CapEx/Revenue-16.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric300451Activity
Op margin-39.4%-24.0% medp25 -212.9% · p75 6.1%below median
Net margin-38.2%-20.7% medp25 -188.5% · p75 4.8%below median
Gross margin31.7%49.8% medp25 36.6% · p75 67.4%bottom quartile
CapEx / revenue-16.4%-4.7% medp25 -11.2% · p75 -1.8%bottom quartile
Debt / equity2.0%3.6% medp25 0.0% · p75 22.2%below median
Observations
IR observations
Mean price target6.37 CNY
Median price target6.38 CNY
High price target6.71 CNY
Low price target6.00 CNY
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.01 CNY
Last actual EPS-0.26 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 03:10 UTCJob: dc386e8f